David DeTomaso

Arsenal Biosciences (United States) — United States

Medicine · Health Sciences

1h-index4citations12works0.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), CRISPR and Genetic Engineering(2), Immunotherapy and Immune Responses(1), Nanoplatforms for cancer theranostics(1), Monoclonal and Polyclonal Antibodies Research(1)

Publications12 total

DINOcell: learning generalizable perturbation effects through self-distillation
2025Open Access
245 Synthetic pathway activators (SPA) enhance CAR-T activity against solid tumors by reducing T cell exhaustion and increasing functional persistence in preclinical studies
Regular and Young Investigator Award Abstracts·2025Open Access
1125 gx1: virtual target identification for overcoming T cell exhaustion
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract 6395: Synthetic pathway activators enhance CAR-T functional persistence and prevent T cell exhaustion
Cancer Research·2025· 1 cited
334 Computational mapping of CAR-T cell exhaustion through single-cell perturbation screens
Regular and Young Investigator Award Abstracts·2024Open Access
282 Improving solid tumor CAR-T therapies by modulating T cell transcriptional states using combinatorial <i>in vitro</i> CRISPR screening followed by <i>in vivo</i> validation
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract 7034: Pooled CRISPR screening coupled with single-cell sequencing identifies modifiers of CAR T cell state in the context of chronic antigen stimulation
Cancer Research·2024
259 Discovery of synthetic signaling pathway receptors that increase the potency of CAR-T cells through optimized STAT activity
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract 4073: Tunable STAT activation by synthetic pathway activators (SPAs) increases engineered T-cell potency and persistence
Cancer Research·2023
332 CRISPR/Cas9-based integration of a large and modular cassette into a safe harbor site to improve CAR T cell therapy efficacy and safety
Regular and Young Investigator Award Abstracts·2022· 2 citedOpen Access
Abstract 2830: Multiplexed shRNAs targeting FAS and PTPN2 enhance CAR T persistence and anti-tumor efficacy
Cancer Research·2022· 1 cited
213 AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells
Regular and Young Investigator Award Abstracts·2021Open Access

Frequent Co-authors

W. Nicholas Haining(10), Aaron Cooper(9), Ashley Cass(9), Levi Gray-Rupp(8), Brendan Galvin(7), Anzhi Yao(5), Suchismita Mohanty(5), Grace Zheng(5), Allyson J. Merrell(5), Julie Chow(5), Lina M León(5), Andrew Cardozo(5), Catherine Oh(5), Azalea Ong(5), Marian Sandoval(5), Lionel Berthoin(4), Matt Drever(4), Thomas J. Gardner(4), Beatriz Millare(4), Jeremy Chen(4)